+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Heparin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4856291
  • Report
  • October 2019
  • Region: Global
  • 104 pages
  • IMARC Group
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Aspen
  • Changshan Pharm
  • Dr. Reddy’s Laboratories
  • Hepalink
  • LeoPharma
  • Pfizer
  • MORE
The global heparin market is expected to grow at a CAGR of around 5% during 2019-2024. Heparin, denoted by the chemical formula C12H19NO20S3, is a sulfur-containing polysaccharide that acts as an anticoagulant or a blood thinner. It prevents the formation of blood clots inside blood vessels and is used for the treatment of heart conditions and unstable angina. It is also used in post-surgeries as well as during dialysis and blood transfusion. Heparin is usually injected directly into the muscle or the veins to break up clots and maintain smooth fluidity of the blood. Some common side-effects of using heparin include easy bruising and itchy skin with redness.

The rising prevalence of various medical ailments such as deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the key factors driving the global market. Also, heparin has been proven to be an extremely effective drug for venous thromboembolism and cardiovascular disorders (CVDs), which is contributing significantly to its market growth. Furthermore, biopharmaceutical companies are developing innovative medicines to enhance the therapeutic potential of heparin and reduce its side-effects. Availability of synthetic and semi-synthetic heparin mimetics that assist in treating various cancers, coagulation and inflammatory diseases is significantly increasing the adoption of the product. The market is further driven by the various advancements in the field of carbohydrate synthesis, which include building block preparation, coupling reactions and the development of convergent strategies. Moreover, increasing government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with ultra-low molecular weight for utilization in chemotherapy are also creating a positive outlook for the market.

The publisher's latest report provides a deep insight into the global heparin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the heparin market in any manner.

Report Coverage:

Historical, Current and Future Market Trends

Market Breakup by Product:
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMWH)

Market Breakup by Source:

Market Breakup by Mode of Administration:

Market Breakup by Application:
Atrial Fibrillation & Heart Attack
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)

Market Breakup by End-User:
Homecare Settings
Ambulatory Surgical Centers

Market Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Stores

Market Breakup by Region:
North America
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being GlaxoSmithKline, Hepalink, Pfizer, LeoPharma, Sanofi, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Aspen, LEO Pharma, Baxter, Changshan Pharm, Sandoz, Opocrin, Deebio, Tiandong, etc.

Key Questions Answered in This Report:
  • How has the global heparin market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global heparin industry?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the source?
  • What is the breakup of the market based on the mode of administration?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global heparin industry?
  • What are the key driving factors and challenges in the global heparin industry?
  • What is the structure of the global heparin industry and who are the key players?
  • What is the degree of competition in the global heparin industry?
Note: Product cover images may vary from those shown
2 of 4


  • Aspen
  • Changshan Pharm
  • Dr. Reddy’s Laboratories
  • Hepalink
  • LeoPharma
  • Pfizer
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Heparin Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Product
5.4 Market Breakup by Source
5.5 Market Breakup by Mode of Administration
5.6 Market Breakup by Application
5.7 Market Breakup by End-User
5.8 Market Breakup by Distribution Channel
5.9 Market Breakup by Region
5.10 Market Forecast

6 Market Breakup by Product
6.1 Unfractionated Heparin
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Low Molecular Weight Heparin (LMWH)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Source
7.1 Bovine
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Porcine
7.2.1 Market Trends
7.2.2 Market Forecast

8 Market Breakup by Mode of Administration
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Parenteral
8.2.1 Market Trends
8.2.2 Market Forecast

9 Market Breakup by Application
9.1 Atrial Fibrillation & Heart Attack
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Stroke
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Deep Vein Thrombosis (DVT)
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Pulmonary Embolism (PE)
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Others
9.5.1 Market Trends
9.5.2 Market Forecast

10 Market Breakup by End-User
10.1 Hospitals
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Clinics
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Homecare Settings
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Ambulatory Surgical Centers
10.4.1 Market Trends
10.4.2 Market Forecast
10.5 Others
10.5.1 Market Trends
10.5.2 Market Forecast

11 Market Breakup by Distribution Channel
11.1 Hospital Pharmacies
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Retail Pharmacies
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Drug Stores
11.3.1 Market Trends
11.3.2 Market Forecast
11.4 Online Stores
11.4.1 Market Trends
11.4.2 Market Forecast
11.5 Others
11.5.1 Market Trends
11.5.2 Market Forecast

12 Market Breakup by Region
12.1 Europe
12.1.1 Market Trends
12.1.2 Market Forecast
12.2 North America
12.2.1 Market Trends
12.2.2 Market Forecast
12.3 Asia Pacific
12.3.1 Market Trends
12.3.2 Market Forecast
12.4 Middle East and Africa
12.4.1 Market Trends
12.4.2 Market Forecast
12.5 Latin America
12.5.1 Market Trends
12.5.2 Market Forecast

13 SWOT Analysis
13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats

14 Value Chain Analysis

15 Porter's Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape
17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
17.3.1 GlaxoSmithKline
17.3.2 Hepalink
17.3.3 Pfizer
17.3.4 LeoPharma
17.3.5 Sanofi
17.3.6 Dr. Reddy's Laboratories
17.3.7 Teva Pharmaceutical Industries
17.3.8 Aspen
17.3.9 LEO Pharma
17.3.10 Baxter
17.3.11 Changshan Pharm
17.3.12 Sandoz
17.3.13 Opocrin
17.3.14 Deebio
17.3.15 Tiandong
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • GlaxoSmithKline
  • Hepalink
  • Pfizer
  • LeoPharma
  • Sanofi
  • Dr. Reddy’s Laboratories
  • Teva Pharmaceutical Industries
  • Aspen
  • LEO Pharma
  • Baxter
  • Changshan Pharm
  • Sandoz
  • Opocrin
  • Deebio
  • Tiandong
Note: Product cover images may vary from those shown
5 of 4